Literature DB >> 18540692

Low frequency of Epstein Barr virus association and high frequency of p53 overexpression in an Argentinean pediatric T-cell lymphoma series.

Paola Chabay1, Elena De Matteo, Mario Lorenzetti, Anahí Vijnovich Barón, Pamela Valva, María Victoria Preciado.   

Abstract

T-cell non-Hodgkin's lymphomas (NHLs) represent 10% to 15% of all diagnosed lymphomas in Western countries. Various geographic frequencies of T-cell NHL have been documented, in part reflecting increased exposure to pathogenic factors such as Epstein-Barr virus (EBV). Our aims were to assess EBV and p53 expression in Argentine pediatric T-cell lymphoma and to correlate them with patients' survival. Epstein-Barr encoded RNAs (EBERs) in situ hybridization and LMP1 and p53 immunohistochemical staining were performed on formalin-fixed paraffin-embedded lymph node biopsies from 25 pediatric T-lymphoma patients. In 17 of 25 samples good-quality DNA was obtained, and EBER polymerase chain reaction was assessed to confirm in situ hybridization and immunohistochemical results. Epstein-Barr virus expression was found in 8.0% of cases. p53-positive staining was distributed in 92% of pediatric cases. Kaplan-Meier survival analysis showed that neither EBV nor p53 expression was statistically significantly associated with event-free survival. Our data showed a low frequency of EBV association with pediatric T-cell lymphoma. It seems that p53 plays an important role in proliferation in our studied population, since it is overexpressed in 92% of T-cell lymphoma cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18540692     DOI: 10.2350/07-11-0378.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  1 in total

1.  Prognostic significance of EBV latent membrane protein 1 expression in lymphomas: evidence from 15 studies.

Authors:  Yuan Mao; Mei Ping Lu; Hong Lin; Da Wei Zhang; Ying Liu; Qing Dong Li; Zhi Gang Lv; Jia Ren Xu; Ren Jie Chen; Jin Zhu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.